Search results
Showing 91 to 105 of 1505 results for patients and public
In development Reference number: GID-TA11340 Expected publication date: TBC
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 07 May 2026
In development Reference number: GID-TA11633 Expected publication date: 18 June 2026
This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.
This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.
View quality statements for QS189Show all sections
Sections for QS189
- Quality statements
- Quality statement 1: Multi-agency suicide prevention partnerships
- Quality statement 2: Reducing access to methods of suicide
- Quality statement 3: Media reporting
- Quality statement 4: Involving family, carers or friends
- Quality statement 5: Supporting people bereaved or affected by a suspected suicide
- Update information
- About this quality standard
In development Reference number: GID-TA10868 Expected publication date: 15 July 2026
In development Reference number: GID-IPG10216 Expected publication date: 04 March 2026
Read biographies for all members of NICE's indicator advisory committee.
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]
In development Reference number: GID-TA11651 Expected publication date: 04 June 2026
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]
In development Reference number: GID-TA11572 Expected publication date: 25 February 2026
Involving you in the development of NICE guidance.
Read biographies for all members of NICE's indicator advisory committee.
In development Reference number: GID-TA10990 Expected publication date: TBC
In development Reference number: GID-TA10143 Expected publication date: TBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]
In development Reference number: GID-TA11638 Expected publication date: TBC